# Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

> **NCT02441894** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 21 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** CABAZITAXEL XRP6258
- **DRUG:** PEG-G-CSF
- **DRUG:** Prednisolone
- **DRUG:** Dexchlorpheniramine or Diphenhydramine
- **DRUG:** Ranitidine
- **DRUG:** Metoclopramide, Granisetron, or Ondansetron
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02441894
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02441894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02441894, "Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02441894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*